Once-weekly semaglutide 2.4 mg reduced the risk for major adverse cardiovascular events among adults with overweight or obesity who were at risk for atherosclerotic cardiovascular disease, according ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback